BIAF
bioAffinity Technologies, Inc.
Key Financials
Revenue
$6.2M
↓ 34.2%
Net Income
$-14909754
↓ 64.9%
Gross Profit
$4336
N/A
Operating Income
$-10572508
↓ 18.1%
EPS (Diluted)
$-8.66
↓ 1054.7%
Total Assets
$11.0M
↑ 68.3%
Cash & Equivalents
$6.4M
↑ 483.5%
Total Liabilities
$3.7M
↓ 5.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/13/2026 | View on SEC |
| PRER14A | 10/13/2026 | View on SEC |
| 8-K | 10/9/2026 | View on SEC |
| 424B5 | 10/9/2026 | View on SEC |
| 424B5 | 10/9/2026 | View on SEC |
| 8-K | 10/8/2026 | View on SEC |
| 8-K | 10/6/2026 | View on SEC |
| 8-K | 9/30/2026 | View on SEC |
| PRE 14A | 9/29/2026 | View on SEC |
| 8-K | 9/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BIAF |
| Company Name | bioAffinity Technologies, Inc. |
| CIK | 1712762 |
| Sector | Services-Commercial Physical & Biological Research |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 8731 |
| SIC Description | Services-Commercial Physical & Biological Research |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 210-698-5334 |